Lancashire and South Cumbria
Formulary
Formulary
10 Musculoskeletal and joint diseases
10-01-01 Non-steroidal anti-inflammatory drugs
Systemic as well as local effects of NSAIDs contribute to gastro–intestinal damage; taking oral formulations with milk or food, or using enteric-coated formulations, or changing the route of administration may only partially reduce symptoms such as dyspepsia.
| Ibuprofen |
|
First Choice
|
Tablets 200mg, 400mg, 600mg
|
 LSCMMG: Over the Counter Items that Should not be Routinely Prescribed in Primary Care Policy MHRA: High-dose ibuprofen (≥2400mg/day): small increase in cardiovascular risk |
|
Solution for infusion 400mg/100mL| Naproxen |
|
First Choice
|
Tablets 250mg, 500mg |
|
LSCMMG: Over the Counter Items that Should not be Routinely Prescribed in Primary Care Policy |
|
|
| Diclofenac |
|
Formulary
|
Tablets e/c 25mg, 50mg
|
|
MHRA: Diclofenac: new contraindications and warnings |
|
|
For short term use in breastfeeding mothers only.
Rheumatology initiation ONLY. When other NSAIDs have been shown to be clinically ineffective.| Etoricoxib |
|
Formulary
|
Tablets 30mg, 60mg, 90mg, 120mg |
|
MHRA: Etoricoxib (Arcoxia): revised dose recommendation for rheumatoid arthritis and ankylosing spondylitis |
|
| Phenylbutazone |
|
Formulary
|
| Tablets 100mg Consultant rheumatologist only. Reserved for ankylosing spondylitis not responsive to other NSAIDs |
|
| Diclofenac |
|
Formulary
|
Suppositories 12.5mg, 25mg, 50mg, 100mg Short-term use only. |
|
MHRA: Diclofenac: new contraindications and warnings |
|
Links
- LSCMMG: Inflammatory Bowel Disease: High Cost Drugs Commissioning Pathway
- LSCMMG: Over the Counter Items that Should not be Routinely Prescribed in Primary Care Policy
- LSCMMG: Over the Counter Items that Should not be Routinely Prescribed in Primary Care Policy
- LSCMMG: Primary Care Constipation Guidelines
- MHRA Drug Safety Update Oct 2016: Etoricoxib (Arcoxia): revised dose recommendation for rheumatoid arthritis and ankylosing spondylitis
- MHRA Drug Safety Update: Contraindications and warnings due to CV risk (2013)
- MHRA Drug Safety Update: Contraindications and warnings due to CV risk (2013)
- MHRA Drug Safety Update: Contraindications and warnings due to CV risk (2013)
- MHRA Drug Safety Update: Contraindications and warnings due to CV risk (2013)
- MHRA Drug Safety Update: Contraindications and warnings due to CV risk (2013)
- MHRA DSU April 2019: Belimumab (Benlysta): increased risk of serious psychiatric events seen in clinical trials
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Diclofenac: new contraindications and warnings
- MHRA: Diclofenac: new contraindications and warnings
- MHRA: Etoricoxib (Arcoxia): revised dose recommendation for rheumatoid arthritis and ankylosing spondylitis
- MHRA: High-dose ibuprofen (≥2400mg/day): small increase in cardiovascular risk
- MHRA: https://www.gov.uk/drug-safety-update/diclofenac-new-contraindications-and-warnings
- MHRA: Non-steroidal anti-inflammatory drugs (NSAIDs): cardiovascular risks
- MHRA: Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy
- NICE CG143:Fever in under 5s: assessment and initial management
- NICE CG147: Diverticular disease: diagnosis and management
- NICE CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE NG1: Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people
- NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus
- NICE TA752:Belimumab for treating active autoantibody-positive systemic lupus erythematosus
- NICE TA806: Belimumab for treating lupus nephritis (terminated appraisal)
- NPC: Diclofenac and CV risk review (2010)
- NPC: Diclofenac and CV risk review (2010)
- NPC: Diclofenac and CV risk review (2010)
- NPC: Diclofenac and CV risk review (2010)
- NPC: Diclofenac and CV risk review (2010)
- NSAID review (UKmi 2013) - naproxen or ibuprofen preferred
- NSAID review (UKMi 2013) - Naproxen or ibuprofen preferred
- NSAID review (UKMi 2013) - Naproxen or ibuprofen preferred
- NSAID review (UKmi 2013) - Naproxen or ibuprofen preferred
- NSAID review (UKMi 2013) - Naproxen or ibuprofen preferred
- NSAID review (UKMi 2013) - Naproxen or ibuprofen preferred
- NSAID review (UKMi 2013) - Naproxen or ibuprofen preferred
- UKMI Q&A: Can breastfeeding mothers take ibuprofen?